Yesterday, $JD.com(JD)$ released its Q4 report and full-year 2022 results.After the announcement, the stock price of JD.com in the US surged by 2% in pre-market trading, but quickly fell back, dropping nearly 1% at one point.The stock price trend provided the best interpretation of the Q4, with some surprising results and some that were not as expected.1. Revenue slightly lower than estimateJD.com's Q4 revenue was CNY 295.45 billion, slightly lower than the analyst estimate of CNY 295.62 billion on Bloomberg. However, the total amount difference was relatively small, and the actual result and expected growth rate were both 7.1%:Merchandise sales revenue was CNY 237.599 billion, only a 1.2% YoY increase; service revenue was CNY 57.847 billi

$Li Auto(LI)$ released its quarterly report, with revenue slightly exceeding market expectations, and the stock price once rose over 7% before the bell.Compared to analysts' expectations, Q4 revenue only slightly exceeded by 0.04%. Adjusted net income greatly exceeded expectations, beating analysts' forecasts by 167.5%.In terms of operating income, Li Auto lost 134 million RMB in the fourth quarter, compared to income of 24.1 million in the same period in 2021. Therefore, the big beat in net income had limited stimulus to the stock price.However, Li Auto's earnings can definitely beat other new energy car companies. Compared to $Tesla Motors(TSLA)$, Li Auto has an advantage in

Some companies experienced roller coaster ride after the earnings release. You can find the stocks that rose or fell most in "Movers & Shakers" on Tiger Trade app.1. $Block(SQ)$ Block stock rose 8% in extended trading after the payments company reported fourth-quarter revenue and gross profit that beat Wall Street's expectations.Here’s how Block did versus consensus expectations: Block posted $1.66 billion in gross profit, up 40% from a year ago. That beat Wall Street expectations of $1.53 billion. Analysts tend to focus on gross profit as a more accurate measurement of the company’s core

Q&A（Question-and-Answer Session）is a session after the company's prepared remarks where institutional investors and analysts ask management questions. In this dialogue, you may find some valuable information that might affect the stock price in the following weeks.Now let's look at some key points from NVIDIA Q4 FY 2023 Q&A Session Transcript$NVIDIA Corp(NVDA)$ Q:Clearly, on this call, a key focal point is going to be the monetization effect of your software and cloud strategy. I think as we look at it, I think, straight up, the enterprise AI software suite, I think, is priced at around $6,000 per CPU socket. I think you've got pricing metrics a little bit higher for the cloud consumption model. I'm just curious, Colette, how do we st

1.$Applied Materials(AMAT)$ AMAT 1QRevenue +7% (as guided per the company)Net Income -4%Dil. EPS +1% (Adj +7%)OCF -15%FCF -21% (higher Capex)2Q FY23 Revenue $6.4 B at mid-point (+2%)AMAT enormous drop in China sales (-42%)2.$Coca-Cola(KO)$ KO announces a 4.6% dividend increaseQuarterly dividend from $0.44 to $0.4661st consecutive annual dividend Increasehttps://twitter.com/DividendWave/status/1626328812957868035

$Analog Devices(ADI)$ ADI with a strong quarter increases dividend1Q YoYRevenue 52%Net Income +243%Dil. EPS +255% (Ajd. 42%)OCF +64%FCF +65%Dividend increases by 13%2Q guidanceRevenue $3.2 B at mid-point (+8%)ADI revenue per segmentADI guidance for 2Q and 2Q actuals from last yearADI announces a 13% dividend raiseFrom $0.76 to $0.86 / share / quarter20 years of consecutive dividend increases12% dividend CAGR for the previous 4 yearsADI Cash flowramping up following the Maxi acquisitionDividend payout at 37%ADI Cash flow per shareDespite the dilution (increase of shares outstanding) due to the Maxim acquisition FCF/share is increasingFY18 to FY22 (CAGR)FCF +20%Shares outstanding +9% FCF/share +10%Div/share +12%https://twitter.com/DividendWave/status

$Coca-Cola(KO)$ KO 4Q and FY results4Q YoYRevenue +7% (case volume -1%)Net Income -16% (Adj. flat)Dil. EPS -16% (Adj. flat)FY22OCF -13%FCF -15%FY23 guidanceorganic revenue (non-GAAP) growth of 7% to 8% comparable EPS (non-GAAP) growth of 4% to 5%KO FY23 guidancehttps://twitter.com/DividendWave/status/1625471234971512834

4.2% dividend yield.Growing production reached a record high of 1,400 MMcf/day.Sustainable EPS and FCF (Free Cash Flow) growth.Lowest-in-the-industry cost structure which helps generate 80% EBITDA margins.Huge FCF growth of 218% to $286 million for 3Q22.Delevering program to reduce Debt-to-EBITDA to 0.9x.Investment ThesisComstock Resources$Comstock Resources(CRK)$ is a Haynesville Basin pure-play natural gas producer closely located to the Gulf Coast corridor and near several large LNG (Liquified Natural Gas) terminals. CRK operates 1,600 wells across 372,000 acres with an average lateral length of 8,520 feet.In 3Q22, CRK generated the highest quarterly free cash flow in the company’s history, amounting to $286 million in FCF, which is $1.92 per sh

While the broader market enter a consolidated stage, some companies experienced roller coaster ride after the earnings release. You can find the stocks that rose or fell most in "Movers & Shakers" on Tiger Trade app.$Affirm Holdings, Inc.(AFRM)$ fell 20%; $Walt Disney(DIS)$ and $Uber(UBER)$ rose nearly 10%.1. $Affirm Holdings, Inc.(AFRM)$

$CVS Health(CVS)$ 4Q YoYRevenue +9.5%Net Income +76% (Adj flat)Dil. Eps +79% (Ajd. +1%)FY22OCF -11% (mostly inventories)FCF -20%CVS 2023 guidanceThat Cash flow from Operation at $12.5 to $13.5 is getting annoying (low ball again?) or one day it will happen?it was $16.2 B in FY22This was CVS guidance over 3QRevenue actuals of $322They seem to consistently under promise (IMaO)CVS cash flow with FY22 completedFCF decline 15% ( due to inventory & prescriptions)Dividend payout at 17%CVS FCF/sharewith FCF declining, FCF per share is at the same level of FY20CVS with a proposed $10.6 B acquisition of Oak Street Health$39 per shareExpected to close in 2023Current Oak Street CEO Mike Pykosz will continue to leadOak Street health will add $2 B in re

Yesterday after the bell, $Apple(AAPL)$ released its fiscal year 2023 quarterly report (corresponding to the fourth quarter of 2022 on a natural day). Revenue declined for the first time since 2019, and after the announcement, Apple's stock price took a dive after hours, eventually closing down 3.24%.Is Apple's earnings really that bad?Looking at Q1, Apple's results remain strong if we remove effects from currency exchange rates and production outages.Media reports made the market think that Apple's earnings were very bad: "Apple's revenue fell badly", "iPhones are not selling" and so on.In terms of expectations, Apple's Q1 revenue and net income were both below the consensus estimates of Bloomberg analysts, and indeed underperformed. Bu

1. $Qualcomm(QCOM)$ QCOM weak 1QYoYRevenue -12% (below their guidance). handsets -18%Net Income -34%Dil. EPS -34%OCF +32%FCF +50%2Q guidancerevenue $9.3 B at mid-point (-18% YoY)EPS $1.63 (-36% at mid-point)QCOM 2Q outlook and 2Q actuals of last year2. $Bristol-Myers Squibb(BMY)$ BMY 4Q weak in-line and new products4Q YoYRevenue -5% (Revlimid -$1 B ; -32% )Net Income -15%Dil. EPS -11% (Adj -1%)FY23 GuidanceRevenue +2%Main BMY weakness from In-Line and New Product PortfolioFY22 Guidance of $36 B fell short by ~$0.6BBMY Revlimid fell 32% (YoY) this quarter and 22% for the yearStill had revenue of ~$10B (better than guided $9.0 B to $9.5 B)FY23 guidance is $6.5 BSo$BMY needs to offset these $3.

$Apple(AAPL)$ AAPL weak 1Q Revenue -5% (iPhone -8%)Net Income -13%Dil EPS -10%OCF -28%FCF -32%AAPL segmentsAAPL Cash flow after 1Qnumbers that put Apple in a league its own• TTM FCF declined $14 B after this quarter• even with this drop, dividend FCF payout at 15%https://twitter.com/DividendWave/status/1621262358877278213

$Altria(MO)$ Altria 4Q with a large cigarette volume lossRevenue -2.3% (cigarette shipment volume -12.1%)Adj Net Income +6% Adj Dil EPS +8.3%new $1 billion share repurchase programFY23 guidanceEPS $4.98 to $5.13 (+3% to 6% from Adj FY22 EPS)MO cigarette volume decline (reported) in FY221Q -6.3%2Q -11.1%3Q -9.7%4Q -12.1%FY -9.7%Largest yearly volume decline since FY09https://twitter.com/DividendWave/status/1620762448428171267

1.$Pfizer(PFE)$ PFE another quarter with Covid related products tailwind turning into a FY23 headwind4Q YoYRevenue +2%Net Income +47%Dil. EPS +48%FY23 guidanceRevenue down from $100 B to $69 B at mid-point31% declinePFE FY23 guidanceThey did not share the Balance Sheet and Cash flow statement, we need to wait for the 10-kBut debt should have increased significantly with the Q4 acquisitions ($18.3 B)Net debt was $1 B at the end of Q3, so I´m guessing it is back to double digits2.$AbbVie(ABBV)$ The day is here ABBV Humira has the first U.S. market competitorThe company has• diversified with Allergan acquisition• 2 giants in the making with Skyrizi & Rinvoqit´s the world highest selling drug at $21 B

1.$Intel(INTC)$ INTC Cash flow with FY22 completedCash flow from Operations down to ~$15 B (-48%)Capex ~$25B (+25%)Free Cash flow at negative ~$9.5 B Intel has previously guided for no FCF for 2023/2024Dividend weighs $6.0 B /yearFrom yesterday´s call on dividendMeanwhile, there is a $0.5B difference in "other assets and liabilities" in Operating Cash flow for FY21 between yesterday´s press release the 10-Kanyone know why?On$INTC dividend question here is the reply (unfortunately I cut the reply):2.With JNJ$Johnson & Johnson(JNJ)$ reporting we got Imbruvica salesImbruvica sales are shared with ABBV4Q Imbruvica JNJ sales show a similar decline to 3QSo ABBV